Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know
Trump’s deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.
How patients are turning to AI chatbots to fight back against the broken $5 trillion healthcare system
On July 29, 2025, at 9:45 a.m., Christine Ressy was supposed to be undergoing surgery to remove kidney stones. Instead, Ressy, a 49-year-old hairdresser in New York City, found herself holding back tears in the waiting room of a Manhattan hospital. Unless she paid half of her $10,933 bill prior to surgery, her doctor simply […]
Study shows Ozempic could help dialysis patients qualify for kidney transplants
Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians reveals that breakthrough weight loss medications could change that—giving more patients a second chance at life.
Over Half Regain Weight After Stopping GLP-1s
The largest real-world study to date of GLP-1 discontinuation finds over half regain weight within a year. Medscape Medical News
High protein breakfasts help you feel fuller but do not change how much you eat later
High protein breakfasts, whether plant or animal-based, boosted GLP-1 and PYY and modestly reduced appetite compared with a low protein, high carbohydrate meal. Despite these hormonal and appetite changes, lunchtime energy intake remained unchanged in both younger and older adults.
Off-label GLP-1 use highlights the cultural pressures driving body anxieties
New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand […]
Pfizer Completes Acquisition of Metsera, Ending Hotly Contested Bidding Offer
Pharmaceutical maker Pfizer announced on Nov. 13 that it had completed its $10 billion acquisition of Metsera, ending a convoluted bidding war for the clinical-stage obesity biotech company. Pfizer purchased all outstanding shares of Metsera stock at $65.60 per share, an enterprise valuation of about $7 billion, with additional contingent value right (CVR) payments of […]
Injectable weight-loss drug helps shift stubborn pounds post-surgery
Some people don’t lose enough weight after bariatric surgery, but a new study shows that adding a daily shot of GLP-1 drug liraglutide can help patients shed extra pounds and may reduce the need for further surgery. Continue Reading Category: Illnesses and conditions, Body and Mind Tags: Obesity, Bariatric surgery, Weight Loss, GLP-1 receptor agonists, […]
Five key questions about GLP-1 weight loss medicines
What we don’t yet know about GLP-1s — and why it’s important to find out.
What the Health? From KFF Health News: The Government Is Open
The Host Emmarie Huetteman KFF Health News Emmarie Huetteman, senior editor, oversees a team of Washington reporters, as well as “Bill of the Month” and “What the Health? From KFF Health News.” She previously spent more than a decade reporting on the federal government, most recently covering surprise medical bills, drug pricing reform, and other health policy […]